Merck's FDA-Approved Subcutaneous Keytruda Secures Patent Protection
The FDA approved an injectable form of Merck's key cancer drug Keytruda, offering a quicker, less invasive alternative to infusions, though Merck's stock declined despite the news. The new formulation aims to maintain sales as biosimilars enter the market and is expected to be adopted by 30-40% of patients within 18-24 months, especially in early-stage cancers.
